Loading...
OTCM
SDZNY
Market cap29bUSD
Dec 02, Last price  
71.38USD
1D
1.30%
1Q
15.54%
IPO
162.41%
Name

Sandoz Group AG

Chart & Performance

D1W1MN
OTCM:SDZNY chart
No data to show
P/E
P/S
3.38
EPS
Div Yield, %
0.70%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
9.12b
-8.60%
9,035,097,3978,794,328,5908,859,184,0189,979,000,0009,121,073,997
Net income
0k
-100.00%
433,639,621830,153,899-22,86177,000,0000
CFO
656m
+81.22%
1,030,598,0611,237,916,7181,168,044,637362,000,000656,000,000
Dividend
May 03, 20240.49836 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
URL
IPO date
Oct 04, 2023
Employees
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT